Skip to content

Comparison of the Effect of 4th Generation Fluoroquinolones, Gatifloxacin and Moxifloxacin, on Epithelial Healing Following Photorefractive Keratectomy (PRK), A Substudy of: Initial Evaluation of Excimer Laser Keratorefractive Surgery in U.S. Army Personnel (WU # 2335-99)

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00414011
Enrollment
40
Registered
2006-12-20
Start date
Unknown
Completion date
2005-02-28
Last updated
2013-07-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Epithelium, Corneal

Keywords

Removal of corneal epithelium followed by excimer laser treatment during prk

Brief summary

The purpose of this study is a prospective,double-blinded, randomized trial to compare the rate of healing following PRK after the use of two commercially available 4th generation fluoroquinolones, moxifloxacin and gatifloxacin.

Interventions

DRUGMoxifloxacin

1 drop 4 times daily for 1 week or until complete re-epithelization (usually 3-4 days) after surgery

1 drop 4 times daily for 1 week or until complete re-epithelization (usually 3-4 days) after surgery

Sponsors

Walter Reed Army Medical Center
Lead SponsorFED

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
21 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Manifest refraction spherical equivalent (MSE) of up to -6.00 diopters (D) at the spectacle plane with refractive cylinder up to 3.00D.

Exclusion criteria

* Concurrent topical or systemic medications that may impair healing including corticosteroids, antimetabolites, isotretinoin, amiodarone hydrochloride and/ or sumatripin. * Patients with known sensitivity or inappropriate responsiveness to any of the medications used in the post-operative course. * Anterior basement membrane dystrophy. * History of recurrent epithelial erosion. * Significant dry eye (symptomatic sith Schirmer \<5mm at 5 minutes) * Other corneal epithelial disorder or healing abnormality

Design outcomes

Primary

MeasureTime frameDescription
Corneal Epithelial Healing Time3 to 4 days after surgerypatients' eyes will be observed daily after surgery until the corneal epithelium has completely healed (usually 3 to 4 days)

Countries

United States

Participant flow

Participants by arm

ArmCount
Moxifloxacin/Gatifloxacin Treatment
Both eyes were treated. Each participant was randomly assigned to either: Group A: Moxifloxacin eyedrops on right eye; Gatifloxacin eyedrops on left eye Group B: Gatifloxacin eyedrops on right eye; Moxifloxacin eyedrops on left eye Eyedrops were given as 1 drop 4 times daily for 1 week or until complete re-epithelization (usually 3-4 days) after surgery
35
Total35

Withdrawals & dropouts

PeriodReasonFG000
Overall StudyPhysician Decision3
Overall StudyWithdrawal by Subject2

Baseline characteristics

CharacteristicMoxifloxacin/Gatifloxacin Treatment
Age, Categorical
<=18 years
0 Participants
Age, Categorical
>=65 years
0 Participants
Age, Categorical
Between 18 and 65 years
35 Participants
Age Continuous33.7 years
STANDARD_DEVIATION 7
Region of Enrollment
United States
35 participants
Sex: Female, Male
Female
16 Participants
Sex: Female, Male
Male
19 Participants

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
— / —
other
Total, other adverse events
0 / 0
serious
Total, serious adverse events
0 / 0

Outcome results

Primary

Corneal Epithelial Healing Time

patients' eyes will be observed daily after surgery until the corneal epithelium has completely healed (usually 3 to 4 days)

Time frame: 3 to 4 days after surgery

ArmMeasureValue (MEDIAN)Dispersion
MoxifloxacinCorneal Epithelial Healing Time4 days to complete epithelial healingFull Range 1
GatifloxacinCorneal Epithelial Healing Time4 days to complete epithelial healingFull Range 1.4

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026